Skip to main content
SpringerLink
Log in

Ösophagus/Magen/Dünndarm

  • Conference paper
Handbuch Gastroenterologie 2010

Part of the book series: Handbuch Update-Seminar ((UPDATESEMINAR))

  • 1153 Accesses

Zusamenfassung

In einer randomisierten Doppelblindstudie wurden 1392 Patienten mit nicht-untersuchter GERD für 4 Wochen täglich mit Rabeprazol 20 mg oder Esomeprazol 20 mg oder Esomeprazol 40 mg behandelt. Ca. 60% der Patienten waren nach 4 Wochen komplett beschwerdefrei. Eine zufriedenstellende Symptomkontrolle wurde in 86–90% der Patienten erreicht. Zwischen den 3 Behandlungsgruppen gab es keine signifikanten Unterschiede.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

1.11 Literatur

  1. Eggleston A, Katelaris PH, Nandurkar S, Thorpe P, Holtmann G. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care — prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Aliment Pharmacol Ther 2009;29:967–78.

    Article  CAS  PubMed  Google Scholar 

  2. Labenz J, Armstrong D, Zetterstrand S, Eklund S, Leodolter A. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis — results from the EXPO study. Aliment Pharmacol Ther 2009;29:959–966.

    Article  CAS  PubMed  Google Scholar 

  3. Labenz J, Armstrong D, Zetterstrand S, Eklund S, Leodolter A. Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis — results from the maintenance phase of the EXPO study. Aliment Pharmacol Ther 2009;29:1165–1171.

    Article  CAS  PubMed  Google Scholar 

  4. Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009;137:80–87.

    Article  CAS  PubMed  Google Scholar 

  5. Gagliardi GS, Shah AP, Goldstein M, Denua-Rivera S, Doghramji K, Cohen S, Dimarino AJ Jr. Effect of zolpidem on the sleep arousal response to nocturnal esophageal acid exposure. Clin Gastroenterol Hepatol 2009;7:948–52.

    Article  CAS  PubMed  Google Scholar 

  6. Lundell L, Miettinen P, Myrvold HE, Hatlebakk JG, Wallin L, Engström C, Julkunen R, Montgomery M, Malm A, Lind T, Walan A; Nordic GERD Study Group. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol 2009;7:1292–8.

    Article  PubMed  Google Scholar 

  7. Malfertheiner SF, Malfertheiner MV, Mönkemüller K, Röhl FW, Malfertheiner P, Costa SD. Gastroesophageal reflux disease and management in advanced pregnancy: a prospective survey. Digestion 2009;79:115–20.

    Article  PubMed  Google Scholar 

  8. Gill SK, O’Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009;104:1541–5.

    Article  CAS  PubMed  Google Scholar 

  9. Gill SK, O’Brien L, Koren G. The safety of histamine 2 (H2) blockers in pregnancy: a meta-analysis. Dig Dis Sci 2009;54:1835–8.

    Article  CAS  PubMed  Google Scholar 

  10. Mastronarde JG, Anthonisen NR, Castro M, Holbrook JT, Leone FT, Teague WG, Wise RA. American Lung Association Asthma Clinical Research Centers. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 2009;360:1487–99.

    Article  CAS  PubMed  Google Scholar 

  11. Peterson KA, Samuelson WM, Ryujin DT, Young DC, Thomas KL, Hilden K, Fang JC. The role of gastroesophageal reflux in exercise-triggered asthma: a randomized controlled trial. Dig Dis Sci 2009;54:564–71.

    Article  PubMed  Google Scholar 

  12. Mohd H, Qua CS, Wong CH, Azman W, Goh KL. Non-cardiac chest pain: prevalence of reflux disease and response to acid suppression in an Asian population. J Gastroenterol Hepatol 2009;24:288–93.

    Article  CAS  PubMed  Google Scholar 

  13. Williams JF, Sontag SJ, Schnell T, Leya J. Non-cardiac chest pain: the long-term natural history and comparison with gastroesophageal reflux disease. Am J Gastroenterol 2009;104:2145–52.

    Article  PubMed  Google Scholar 

  14. Jaspersen D, Nocon M, Labenz J, Leodolter A, Richter K, Stolte M, Vieth M, Lind T, willich SN, Malfertheiner P. Clinical course of laryngo-respiratory symptoms in gastro-oesophageal reflux disease during routine care — a 5-year follow-up. Aliment Pharmacol Ther 2009;29:1172–1178.

    Article  CAS  PubMed  Google Scholar 

  15. Corley DA, Kubo A, Levin TR, Block G, Habel L, Rumore G, Quesenberry C, Buffler P. Race, ethnicity, sex and temporal differences in Barrett’s oesophagus diagnosis: a large community-based study, 1994-2006. Gut 2009;58:182–8.

    Article  CAS  PubMed  Google Scholar 

  16. Kubo A, Levin TR, Block G, Rumore GJ, Quesenberry CP Jr, Buffler P, Corley DA. Alcohol types and sociodemographic characteristics as risk factors for Barrett’s esophagus. Gastroenterology 2009;136:806–15.

    Article  PubMed  Google Scholar 

  17. Anderson LA, Cantwell MM, Watson RG, Johnston BT, Murphy SJ, Ferguson HR, McGuigan J, Comber H, Reynolds JV, Murray LJ. The association between alcohol and reflux esophagitis, Barrett’s esophagus, and esophageal adenocarcinoma. Gastroenterology 2009;136:799–805.

    Article  PubMed  Google Scholar 

  18. de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of Colorectal Cancer in Patients With Barrett’s Esophagus: A Dutch Population-Based Study. Am J Gastroenterol 2009 Sep 1. [Epub ahead of print]

    Google Scholar 

  19. Abrams JA, Kapel RC, Lindberg GM, Saboorian MH, Genta RM, Neugut Al, Lightdale CJ. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol 2009;7:736–42.

    Article  PubMed  Google Scholar 

  20. Nguyen DM, El-Serag HB, Henderson L, Stein D, Bhattacharyya A, Sampliner RE. Medication usage and the risk of neoplasia in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 2009;7:1299–304.

    Article  PubMed  Google Scholar 

  21. Spechler SJ, Barker PN, Silberg DG. Clinical trial: intragastric acid control in patients who have Barrett’s oesophagus-comparison of once-and twice-daily regimens of esomeprazole and lansoprazole. Aliment Pharmacol Ther 2009;30:138–45.

    Article  CAS  PubMed  Google Scholar 

  22. Wang JS, Varro A, Lightdale CJ, Lertkowit N, Slack KN, Fingerhood ML, Tsai WY, Wang TC, Abrams JA. Elevated Serum Gastrin Is Associated With a History of Advanced Neoplasia in Barrett’s Esophagus. Am J Gastroenterol 2009 Nov 10. [Epub ahead of print]

    Google Scholar 

  23. Barthel JS, Kucera ST, Lin JL, Hoffe SE, Strosberg JR, Ahmed I, Dilling TJ, Stevens CW. Does Barrett’s esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus? Gastrointest Endosc 2009, [Epub ahead of print]

    Google Scholar 

  24. Prasad GA, Alexander JA, Schleck CD, Zinsmeister AR, Smyrk TC, Elias RM, Locke GR 3rd, Talley NJ. Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol 2009;7:1055–61.

    Article  PubMed  Google Scholar 

  25. Veerappan GR, Perry JL, Duncan TJ, Baker TP, Maydonovitch C, Lake JM, Wong RK, Osgard EM. Prevalence of eosinophilic esophagitis in an adult population undergoing upper endoscopy: a prospective study. Clin Gastroenterol Hepatol 2009;7:420–6.

    Article  PubMed  Google Scholar 

  26. Dellon ES, Gibbs WB, Fritchie KJ, Rubinas TC, Wilson LA, Woosley JT, Shaheen NJ. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2009;7:1305–13.

    Article  PubMed  Google Scholar 

  27. Peterson KA, Thomas KL, Hilden K, Emerson LL, Wills JC, Fang JC. Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis. Dig Dis Sci 2009 Jun 18. [Epub ahead of print].

    Google Scholar 

  28. Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith D, Patel J, Byrne M, Simon HU. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomized, placebo-controlled, double-blind trial. Gut 2009 Oct 13. [Epub ahead of print]

    Google Scholar 

  29. Schoepfer AM, Gonsalves N, Bussmann C, Conus S, Simon HU, Straumann A, Hirano I. Esophageal Dilation in Eosinophilic Esophagitis: Effectiveness, Safety, and Impact on the Underlying Inflammation. Am J Gastroenterol 2009 Nov 24. [Epub ahead of print]

    Google Scholar 

  30. Atkins D, Kramer R, Capocelli K, Lovell M, Furuta GT. Eosinophilic esophagitis: the newest esophageal inflammatory disease. Nat Rev Gastroenterol Hepatol 2009;6:267–78.

    Article  PubMed  Google Scholar 

  31. Rothenberg ME. Biology and treatment of eosinophilic esophagitis Gastroenterology 2009;137:1238–49.

    Article  CAS  PubMed  Google Scholar 

  32. Wang C, Yuan Y, Hunt RH. Helicobacter pylori infection and Barrett’s esophagus: a systematic review and meta-analysis. Am J Gastroenterol 2009;104:492–500.

    Article  PubMed  Google Scholar 

  33. Luther J, Dave M, Higgins PD, Kao JY. Association between Helicobacter pylori infection and inflammatory bowel disease: A meta-analysis and systematic review of the literature. Inflamm Bowel Dis 2009 Sep 16. [Epub ahead of print]

    Google Scholar 

  34. Wueppenhorst N, Stueger HP, Kist M, Glocker E. Identification and molecular characterization of triple-and quadruple-resistant Helicobacter pylori clinical isolates in Germany. Antimicrob Chemother 2009;63:648–53.

    Article  CAS  Google Scholar 

  35. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric Quadruple vs. Triple Therapy for Primary Treatment of Helicobacter pylori Infection: Systematic Review and Meta-Analysis of Efficacy and Tolerability. Am J Gastroenterol 2009, Sep 15. [Epub ahead of print]

    Google Scholar 

  36. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009;104:3069–79.

    Article  CAS  PubMed  Google Scholar 

  37. Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY. Sequential and Concomitant Therapy with 4 Drugs are Equally Effective for Eradication of H. pylori Infection. Clin Gastroenterol Hepatol 2009 Oct 3. [Epub ahead of print]

    Google Scholar 

  38. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009;14:109–18.

    Article  CAS  PubMed  Google Scholar 

  39. Schrauwen RW, Janssen MJ, de Boer WA. Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication. Neth J Med 2009;67:96–101.

    CAS  PubMed  Google Scholar 

  40. Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ, Tsai PY, Wu IC, Wang SW, Li CJ, Weng BC, Chang LL, Jan CM, Wang WM, Wu DC. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 2009;63:1017–24.

    Article  CAS  PubMed  Google Scholar 

  41. Bago J, Pevec B, Tomić M, Marusić M, Bakula V, Bago P. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wien Klin Wochenschr 2009;121:47–52.

    Article  CAS  PubMed  Google Scholar 

  42. Fischbach W, Malfertheiner P, Hoffmann JC, Bolten W, Bornschein J, Götze O, Höhne W, Kist M, Koletzko S, Labenz J, Layer P, Miehlke S, Morgner A, Peitz U, Preiss JC, Prinz C, Rosien U, Schmidt WE, Schwarzer A, Suerbaum S, Timmer A, Treiber G, Vieth M. [S3-guideline “Helicobacter pylori and gastroduodenal ulcer disease”] Z Gastroenterol 2009;47:68–102.

    Article  CAS  PubMed  Google Scholar 

  43. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009;137:1641–8.

    Article  PubMed  Google Scholar 

  44. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009;151(2):121–8.

    PubMed  Google Scholar 

  45. Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel JB. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009;113:1231–40.

    Article  CAS  PubMed  Google Scholar 

  46. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009;374:119–25.

    Article  CAS  PubMed  Google Scholar 

  47. Ng FH, Wong SY, Lam KF, Chu WM, Chance P, Ling YH, Kng C, Yuen WC, Lau YK, Kwan A, Wong BC. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 2009 Oct 15. [Epub ahead of print

    Google Scholar 

  48. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937–44.

    Article  CAS  PubMed  Google Scholar 

  49. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713–8.

    PubMed  Google Scholar 

  50. Gupta E, Bansal D, Sotos J, Olden K. Risk of Adverse Clinical Outcomes with Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Percutaneous Coronary Intervention. Dig Dis Sci 2009 Sep 3. [Epub ahead of print]

    Google Scholar 

  51. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009;120:2322–9.

    Article  CAS  PubMed  Google Scholar 

  52. O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989–97.

    Article  PubMed  Google Scholar 

  53. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354–62.

    Article  CAS  PubMed  Google Scholar 

  54. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Fernères J, Danchin N, Becquemont L. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363–75.

    Article  CAS  PubMed  Google Scholar 

  55. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2009;7:1314–21.

    Article  CAS  PubMed  Google Scholar 

  56. Stanley AJ, Ashley D, Dalton HR, Mowat C, Gaya DR, Thompson E, Warshow U, Groome M, Cahill A, Benson G, Blatchford O, Murray W. Outpatient management of patients with low-risk upper-gastrointestinal haemorrhage: multicentre validation and prospective evaluation. Lancet 2009;373:42–7.

    Article  CAS  PubMed  Google Scholar 

  57. Wong GL, Wong VW, Chan Y, Ching JY, Au K, Hui AJ, Lai LH, Chow DK, Siu DK, Lui YN, Wu JC, To KF, Hung LC, Chan HL, Sung JJ, Chan FK. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 2009;137:525–31.

    Article  PubMed  Google Scholar 

  58. Ananthakrishnan AN, McGinley EL, Saeian K. Outcomes of weekend admissions for upper gastrointestinal hemorrhage: a nationwide analysis. Clin Gastroenterol Hepatol 2009;7:296–302.

    Article  PubMed  Google Scholar 

  59. Shaheen AA, Kaplan GG, Myers RP. Weekend versus weekday admission and mortality from gastrointestinal hemorrhage caused by peptic ulcer disease. Clin Gastroenterol Hepatol 2009;7:303–10.

    Article  PubMed  Google Scholar 

  60. Ananthakrishnan AN, McGinley EL, Saeian K. Higher hospital volume is associated with lower mortality in acute nonvariceal upper-GI hemorrhage. Gastrointest Endosc 2009;70:422–32.

    Article  PubMed  Google Scholar 

  61. Sung JJ, Barkun A, Kuipers EJ, Mössner J, Jensen DM, Stuart R, Lau JY, Ahlbom H, Kilhamn J, Lind T; Peptic Ulcer Bleed Study Group. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med 2009;150:455–64.

    PubMed  Google Scholar 

  62. Carmack SW, Genta RM, Schuler CM, Saboorian MH. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am J Gastroenterol 2009;104:1524–32.

    Article  PubMed  Google Scholar 

  63. Genta RM, Schuler CM, Robiou CI, Lash RH. No association between gastric fundic gland polyps and gastrointestinal neoplasia in a study of over 100,000 patients. Clin Gastroenterol Hepatol 2009;7:849–54.

    Article  PubMed  Google Scholar 

  64. Carmack SW, Genta RM, Graham DY, Lauwers GY Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol 2009;6:331–41.

    Article  PubMed  Google Scholar 

  65. Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009;137:1912–33.

    Article  CAS  PubMed  Google Scholar 

  66. Leong RW, Nguyen NQ, Meredith CG, Al-Sohaily S, Kukic D, Delaney PM, Murr ER, Yong J, Merrett ND, Biankin AV. In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease. Gastroenterology 2008;135:1870–6.

    Article  PubMed  Google Scholar 

  67. Kurppa K, Collin P, Viljamaa M, Haimila K, Saavalainen P, Partanen J, Laurila K, Huhtala H, Paasikivi K, Mäki M, Kaukinen K. Diagnosing mild enteropathy celiac disease: a randomized, controlled clinical study. Gastroenterology 2009;136:816–23.

    Article  PubMed  Google Scholar 

  68. Green PH, Yang J, Cheng J, Lee AR, Harper JW, Bhagat G. An association between microscopic colitis and celiac disease. Clin Gastroenterol Hepatol 2009;7:1210–6.

    Article  PubMed  Google Scholar 

  69. Gao Y, Kristinsson SY, Goldin LR, Björkholm M, Caporaso NE, Landgren O. Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology 2009;136:91–8.

    Article  PubMed  Google Scholar 

  70. Daum S, Ipszynski R, Schumann M, Wahnschaffe U, Zeitz M, Ullrich R. High rates of complications and substantial mortality in both types of refractory sprue. Eu J Gastroenterol Hepatol 2009;21:66–70

    Article  Google Scholar 

  71. Lauritano EC, Gabrielli M, Scarpellini E, Ojetti V, Roccarina D, Villita A, Fiore E, Flore R, Santoliquido A, Tondi P, Gasbarrini G, Ghirlanda G, Gasbarrini A. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009;13:111–6.

    CAS  PubMed  Google Scholar 

  72. Lanas A, Garcîa-Rodrîguez LA, Polo-Tomás M, Ponce M, Alonso-Abreu I, Perez-Aisa MA, Perez-Gisbert J, Bujanda L, Castro M, Muñoz M, Rodrigo L, Calvet X, Del-Pino D, Garcia S. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009 Jul;104(7):1633–41. Epub 2009 May 5.

    Article  PubMed  Google Scholar 

  73. Gerson LB, Batenic MA, Newsom SL, Ross A, Semrad CE. Long-term outcomes after double-balloon enteroscopy for obscure gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2009 Jun;7(6):664–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Deutschland

    Prof. Dr. Stephan Miehlke

Authors
  1. Prof. Dr. Stephan Miehlke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kiinik für Aiigemein- und Viszeraichirurgie, Dr. Horst Schmidt Kiiniken GmbH, Ludwig-Erhard-Straße 100, 65199, Wiesbaden

    Christian Eli

  2. Medizinische Klinik, Israelitisches Krankenhaus, Orchideenstieg 14, 22297, Hamburg

    Peter Layer

  3. II. Medizinische Kiinik, Kiinikum Aschaffenburg, Am Hasenkopf 1, 63739, Aschaffenburg

    Wolfgang Fischbach

  4. Chirurgisches Zentrum Viszeral-, Gefäß- und Endokrine Chirurgie, HELlOS Kiinikum Wuppertal, Heusnerstraße 40, 42283, Wuppertai

    Hubert Zirngibl

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Medizin Verlag Heidelberg

About this paper

Cite this paper

Miehlke, S. (2010). Ösophagus/Magen/Dünndarm. In: Eli, C., Layer, P., Fischbach, W., Zirngibl, H. (eds) Handbuch Gastroenterologie 2010. Handbuch Update-Seminar. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-11635-3_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-11635-3_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-11634-6

  • Online ISBN: 978-3-642-11635-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation